Abstract
Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00536 JCO Precision Oncology no. 7 (2023) e2200536. Published online February 21, 2023. Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma Baldeep Wirk , MD1xBaldeep WirkSearch for articles by this author; Jozef Malysz, MD1xJozef MalyszSearch for articles by this author; Esther Choi, MD1xEsther ChoiSearch for articles by this author; and Natthapol Songdej, MD1xNatthapol SongdejSearch for articles by this author Show More 1Penn State College of Medicine, Hershey, PA https://doi.org/10.1200/PO.22.00536 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyPRIOR PRESENTATIONThe abstract of this manuscript was previously presented as a poster at the American Society of Transplantation & Cellular Therapy Meetings, Salt Lake City, UT, April 23-26, 2022.AUTHOR CONTRIBUTIONSConception and design: Baldeep Wirk, Jozef Malysz, Natthapol SongdejAdministrative support: Natthapol SongdejCollection and assembly of data: Baldeep Wirk, Jozef Malysz, Natthapol SongdejData analysis and interpretation: Baldeep Wirk, Jozef Malysz, Natthapol SongdejManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Natthapol SongdejConsulting or Advisory Role: Blueprint MedicinesNo other potential conflicts of interest were reported.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call